Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 4/2011

01-12-2011 | Original Paper

Multidrug resistance strength of the novel multidrug resistance gene HA117: compared with MRP1

Authors: Lihua Zhao, Yanhui Sun, Xiaoqing Li, Xianqing Jin, Youhua Xu, Zhenhua Guo, Rui Liang, Xionghui Ding, Tingfu Chen, Siqi Wang

Published in: Medical Oncology | Issue 4/2011

Login to get access

Abstract

The novel gene HA117 is a multidrug resistance (MDR) gene in all-trans retinoic acid resistance HL-60 cells. The transduction of adenovirus vectors encoding HA117 conferred breast cancer cell line 4T1 MDR not only to MRP1 substrate drugs but also to MRP1 non-substrate drugs and the MDR strength of HA117 was similar to that of multidrug resistance-associated protein-1 (MRP1) for MRP1 substrate, but HA117 had no daunorubicin-excretion function.
Literature
1.
Zheng GH, Fu JR, Xu YH, et al. Screening and cloning of multi-drug resistant genes in HL-60/MDR cells. Leuk Res. 2009;33(8):1120–3.PubMedCrossRef
2.
Guo Y, Zheng G, Jin X, et al. HA117 gene increased the multidrug resistance of K562 cells in vitro: an investigation to the function of a novel gene related to drug resistance. J Exp Clin Cancer Res. 2009;28:63.PubMedCrossRef
3.
Luo J, Deng ZL, Luo X, et al. A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat Protoc. 2007;2(5):1236–47.PubMedCrossRef
4.
Klein I, Sarkadi B, Váradi A. An inventory of the human ABC proteins. Biochim Biophys Acta. 1999;1461(2):237–62.PubMedCrossRef
5.
Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A. 1998;95(26):15665–70.PubMedCrossRef
6.
Goda K, Bacsó Z, Szabó G. Multidrug resistance through the spectacle of P-glycoprotein. Curr Cancer Drug Targets. 2009;9(3):281–97.PubMedCrossRef
7.
Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta. 1976;455(1):152–62.PubMedCrossRef
8.
Shikawa T, Nakagawa H. Human ABC transporter ABCG2 in cancer chemotherapy and pharmacogenomics. J Exp Ther Oncol. 2009;8(1):5–24.
9.
Higgins CF. ABC transporters: physiology, structure and mechanism–an overview. Res Microbiol. 2001;152(3–4):205–10.PubMedCrossRef
10.
Fine RL, Chambers TC, Sachs CW. P-Glycoprotein, multidrug resistance and protein kinase C. Oncologist. 1996;1(4):261–8.PubMed
11.
Warrell RP Jr, Frankel SR, Miller WH Jr, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med. 1991;324(20):1385–93.PubMedCrossRef
12.
Shen ZX, Shi ZZ, Fang J, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. J Proc Natl Acad Sci U S A. 2004;101(15):5328–35.CrossRef
13.
Bellos F, Mahlknecht U. Valproic acid and all-trans retinoic acid: meta-analysis of a palliative treatment regimen in AML and MDS patients. Onkologie. 2008;31(11):629–33.PubMedCrossRef
14.
Gallagher RE. Retinoic acid resistance in acute promyelocytic leukemia. Leukemia. 2002;16(10):1940–58.PubMedCrossRef
15.
Lo Coco F, Ammatuna E, Sanz MA. Current treatment of acute promyelocytic leukemia. Haematologica. 2007;92(3):289–91.PubMedCrossRef
16.
Zhou DC, Kim SH, Ding W, et al. Frequent mutations in the ligand-binding domain of PML–RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo. Blood. 2002;99(4):1356–63.PubMedCrossRef
17.
Wang S, Tricot G, Shi L, et al. RARalpha2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma. Blood. 2009;114(3):600–7.PubMedCrossRef
18.
Heuser M, Argiropoulos B, Kuchenbauer F, et al. MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML. Blood. 2007;110(5):1639–47.PubMedCrossRef
19.
Komura N, Ikeda Y, Masuda N, et al. Designed ATRA analogue active against ATRA-resistant acute promyelocytic leukemia cells having a single nucleotide substitution in their retinoic acid receptor. Leuk Res. 2007;31(3):301–13.PubMedCrossRef
20.
Naoki T, Sumio M, Chihiro K, et al. The possibility of simvastatin as a chemotherapeutic agent for all-trans retinoic acid-resistant promyelocytic leukemia. Biol Pharm Bull. 2008;31(3):369–74.CrossRef
21.
Herst PM, Hesketh EL, Ritchie DS, et al. Glycolytic metabolism confers resistance to combined all-trans retinoic acid and arsenic trioxide-induced apoptosis in HL60rho0 cells. Leuk Res. 2008;32(2):327–33.PubMedCrossRef
22.
Zang G, Miao L, Mu Y, et al. Adenoviral mediated transduction of adenoid cystic carcinoma by human TRAIL gene driven with hTERT tumor specific promoter induces apoptosis. Cancer Biol Ther. 2009;8(10):966–72.PubMedCrossRef
23.
Campos SK, Barry MA. Current advances and future challenges in Adenoviral vector biology and targeting. Curr Gene Ther. 2007;7(3):189–204.PubMedCrossRef
Metadata
Title
Multidrug resistance strength of the novel multidrug resistance gene HA117: compared with MRP1
Authors
Lihua Zhao
Yanhui Sun
Xiaoqing Li
Xianqing Jin
Youhua Xu
Zhenhua Guo
Rui Liang
Xionghui Ding
Tingfu Chen
Siqi Wang
Publication date
01-12-2011
Publisher
Springer US
Published in
Medical Oncology / Issue 4/2011
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9624-y

Other articles of this Issue 4/2011

Medical Oncology 4/2011 Go to the issue

Original Paper

Presentation and outcomes of patients aged 30 years and younger with colorectal cancer: a 20-year retrospective review

Original paper

Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy

Original Paper

Establishment and characterization of an HPV16 E6/E7-expressing oral squamous cell carcinoma cell line with enhanced tumorigenicity

Original Paper

Pro-apoptotic protein BIM in apoptosis of glucocorticoid-sensitive and -resistant acute lymphoblastic leukemia CEM cells

Original Paper

Phase I/II randomised study of a novel erythropoiesis-stimulating agent (AMG 114) for the treatment of anaemia with concomitant chemotherapy in patients with non-myeloid malignancies

Original Paper

Down-regulation of phospho-non-receptor Src tyrosine kinases contributes to growth inhibition of cervical cancer cells
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits